Literature DB >> 20561184

Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.

M J Kovacs1, S R Kahn, P S Wells, D A Anderson, I Chagnon, G LE Gal, S Solymoss, M Crowther, A Perrier, T Ramsay, M T Betancourt, R H White, L Vickars, M A Rodger.   

Abstract

BACKGROUND: Previous studies are mixed as to whether patients with unprovoked pulmonary embolism (PE) have a higher rate of venous thromboembolism (VTE) recurrence after anticoagulation is discontinued than patients with unprovoked deep vein thrombosis (DVT).
OBJECTIVES: To determine whether patients with unprovoked PE have a higher rate of VTE recurrence than patients with unprovoked DVT in a prospective multicenter cohort study. PATIENTS/
METHODS: Six hundred and forty-six patients with a first episode of symptomatic unprovoked VTE were treated with heparin and subsequent oral anticoagulation for 5-7 months, and were followed every 6 months for recurrent VTE after their anticoagulant therapy was discontinued.
RESULTS: Of 646 patients, 194 had isolated PE, 339 had isolated DVT, and 113 had both DVT and PE. After a mean of 18 months of follow-up, there were 91 recurrent VTE events (9.5% annualized risk of recurrent VTE in the total population). The crude recurrent VTE rate for the isolated PE, isolated DVT and DVT and PE groups were 7.7%, 16.5% and 17.7%, respectively. The relative risk of recurrent VTE for isolated DVT vs. isolated PE was 2.1 (95% confidence interval 1.2-3.7).
CONCLUSIONS: This study has demonstrated that patients with a first episode of unprovoked isolated DVT are 2.1 times more likely to have a recurrent VTE episode than patients with a first episode of unprovoked isolated PE. These findings need to be considered when determining the optimal duration of anticoagulant therapy for patients with unprovoked VTE.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561184     DOI: 10.1111/j.1538-7836.2010.03958.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique.

Authors:  Kirsten van Langevelde; Alexandr Srámek; Patrice W J Vincken; Jan-Kees van Rooden; Frits R Rosendaal; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

Review 2.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

3.  Risk of Pulmonary Embolism After Cerebral Venous Thrombosis.

Authors:  Ava L Liberman; Alexander E Merkler; Gino Gialdini; Steven R Messé; Michael P Lerario; Santosh B Murthy; Hooman Kamel; Babak B Navi
Journal:  Stroke       Date:  2017-02-22       Impact factor: 7.914

Review 4.  Optimal duration of anticoagulation in patients with venous thromboembolism.

Authors:  Paolo Prandoni; Chiara Piovella; Luca Spiezia; Fabio Dalla Valle; Raffaele Pesavento
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

Review 5.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

6.  Incidence and Predictors of Recurrence and Mortality Following First Venous Thromboembolism Among the Saudi Population: Single-Center Cohort Study.

Authors:  Fahad A S AlEidan; Reem K AlManea; Alyah T AlMoneef; Nada A Shalash; Norah A AlRajhi; Sarah F AlMousa; Abdulrahman Al Raizah; Khadega A Abuelgasim
Journal:  Int J Gen Med       Date:  2022-09-28

Review 7.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17

Review 8.  Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.

Authors:  Anna Lichota; Eligia M Szewczyk; Krzysztof Gwozdzinski
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.